These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 26747088)

  • 1. Striatal Reward Activity and Antipsychotic-Associated Weight Change in Patients With Schizophrenia Undergoing Initial Treatment.
    Nielsen MØ; Rostrup E; Wulff S; Glenthøj B; Ebdrup BH
    JAMA Psychiatry; 2016 Feb; 73(2):121-8. PubMed ID: 26747088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopamine, Striatum, Antipsychotics, and Questions About Weight Gain.
    Kapur S; Marques TR
    JAMA Psychiatry; 2016 Feb; 73(2):107-8. PubMed ID: 26746880
    [No Abstract]   [Full Text] [Related]  

  • 3. The relation between dopamine D
    Wulff S; Nielsen MØ; Rostrup E; Svarer C; Jensen LT; Pinborg L; Glenthøj BY
    Psychol Med; 2020 Jan; 50(2):220-228. PubMed ID: 30642415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Striatal D(2/3) Binding Potential Values in Drug-Naïve First-Episode Schizophrenia Patients Correlate With Treatment Outcome.
    Wulff S; Pinborg LH; Svarer C; Jensen LT; Nielsen MØ; Allerup P; Bak N; Rasmussen H; Frandsen E; Rostrup E; Glenthøj BY
    Schizophr Bull; 2015 Sep; 41(5):1143-52. PubMed ID: 25698711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Volume increases in putamen associated with positive symptom reduction in previously drug-naive schizophrenia after 6 weeks antipsychotic treatment.
    Li M; Chen Z; Deng W; He Z; Wang Q; Jiang L; Ma X; Wang Y; Chua SE; Cheung C; McAlonan GM; Sham PC; Collier DA; Gong Q; Li T
    Psychol Med; 2012 Jul; 42(7):1475-83. PubMed ID: 22030695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Negative Symptoms and Reward Disturbances in Schizophrenia Before and After Antipsychotic Monotherapy.
    Nielsen MØ; Rostrup E; Broberg BV; Wulff S; Glenthøj B
    Clin EEG Neurosci; 2018 Jan; 49(1):36-45. PubMed ID: 29145751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frontal fasciculi and psychotic symptoms in antipsychotic-naive patients with schizophrenia before and after 6 weeks of selective dopamine D2/3 receptor blockade.
    Ebdrup BH; Raghava JM; Nielsen MØ; Rostrup E; Glenthøj B
    J Psychiatry Neurosci; 2016 Mar; 41(2):133-41. PubMed ID: 26599135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study.
    Olié JP; Spina E; Murray S; Yang R
    Int Clin Psychopharmacol; 2006 May; 21(3):143-51. PubMed ID: 16528136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute weight gain induced by amisulpride monotherapy in a first-episode schizophrenic patient.
    Papadimitriou GN; Theleritis CG; Dikeos DG; Psarros CJ; Soldatos CR
    Int Clin Psychopharmacol; 2006 May; 21(3):181-4. PubMed ID: 16528141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is amisulpride an 'atypical' atypical antipsychotic agent?
    Lecrubier Y
    Int Clin Psychopharmacol; 2000 Dec; 15 Suppl 4():S21-6. PubMed ID: 11252520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 6-week, randomized, multicentre, open-label study comparing efficacy and tolerability of amisulpride at a starting dose of 400 mg/day versus 800 mg/day in patients with acute exacerbations of schizophrenia.
    Lee SJ; Lee JH; Jung SW; Koo BH; Choi TY; Lee KH
    Clin Drug Investig; 2012 Nov; 32(11):735-45. PubMed ID: 23018281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amisulpride is an "atypical" antipsychotic associated with low weight gain.
    Leucht S; Wagenpfeil S; Hamann J; Kissling W
    Psychopharmacology (Berl); 2004 Apr; 173(1-2):112-5. PubMed ID: 14647963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Blocking D2/D3 Receptors on Mismatch Negativity and P3a Amplitude of Initially Antipsychotic Naïve, First Episode Schizophrenia Patients.
    Düring S; Glenthøj BY; Oranje B
    Int J Neuropsychopharmacol; 2015 Oct; 19(3):pyv109. PubMed ID: 26453696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evaluation of efficacy and tolerance of amisulpride in treatment of schizophrenic psychoses].
    Chabannes JP; Pelissolo A; Farah S; Gerard D
    Encephale; 1998; 24(4):386-92. PubMed ID: 9809244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neocortical serotonin2A receptor binding predicts quetiapine associated weight gain in antipsychotic-naive first-episode schizophrenia patients.
    Rasmussen H; Ebdrup BH; Oranje B; Pinborg LH; Knudsen GM; Glenthøj B
    Int J Neuropsychopharmacol; 2014 Nov; 17(11):1729-36. PubMed ID: 24830305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement of brain reward abnormalities by antipsychotic monotherapy in schizophrenia.
    Nielsen MO; Rostrup E; Wulff S; Bak N; Broberg BV; Lublin H; Kapur S; Glenthoj B
    Arch Gen Psychiatry; 2012 Dec; 69(12):1195-204. PubMed ID: 22868877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Striatal response to reward anticipation: evidence for a systems-level intermediate phenotype for schizophrenia.
    Grimm O; Heinz A; Walter H; Kirsch P; Erk S; Haddad L; Plichta MM; Romanczuk-Seiferth N; Pöhland L; Mohnke S; Mühleisen TW; Mattheisen M; Witt SH; Schäfer A; Cichon S; Nöthen M; Rietschel M; Tost H; Meyer-Lindenberg A
    JAMA Psychiatry; 2014 May; 71(5):531-9. PubMed ID: 24622944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea.
    Lee NY; Kim SH; Cho SJ; Chung YC; Jung IK; Kim CY; Kim DH; Lee DG; Lee YH; Lim WJ; Na YS; Shin SE; Woo JM; Yoon JS; Yoon BH; Ahn YM; Kim YS
    Int Clin Psychopharmacol; 2014 Sep; 29(5):279-87. PubMed ID: 24583566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined use of amisulpride and clozapine for patients with treatment-resistant schizophrenia.
    Cook B; Hoogenboom G
    Australas Psychiatry; 2004 Mar; 12(1):74-6. PubMed ID: 15715745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No association of antipsychotic agent-induced weight gain with a DA receptor gene polymorphism and therapeutic response.
    Zhang ZJ; Yao ZJ; Zhang XB; Chen JF; Sun J; Yao H; Hou G; Zhang XB
    Acta Pharmacol Sin; 2003 Mar; 24(3):235-40. PubMed ID: 12617772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.